Omega-3 Fatty Acids for Hypertriglyceridemia: AHA's Latest Science Advisory
Dr. Kumar’s Take:
The American Heart Association (AHA) has reinforced the role of omega-3 fatty acids in managing hypertriglyceridemia (high triglycerides), with updated insights on EPA-only vs. EPA+DHA formulations. This review supports the use of 4g/day prescription n-3 FAs for triglyceride reduction and highlights cardiovascular benefits observed in key trials.
Brief Summary:
This comprehensive AHA science advisory evaluates the efficacy, safety, and clinical implications of omega-3 fatty acids for hypertriglyceridemia management. The review highlights that prescription doses (≥4 g/day) of n-3 FAs, whether EPA-only or EPA+DHA, can lower triglycerides by 20–30% in individuals with moderately high triglycerides (200–499 mg/dL) and ≥30% in those with very high triglycerides (≥500 mg/dL). The REDUCE-IT trial showed a 25% reduction in major adverse cardiovascular events with EPA-only therapy in high-risk patients. While EPA-only formulations appear neutral on LDL-C, EPA+DHA may increase LDL-C in some cases.